Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1978 2
1979 1
1980 1
1981 3
1982 3
1983 1
1984 4
1985 1
1986 5
1987 5
1988 3
1989 1
1990 4
1991 4
1992 4
1993 5
1994 4
1995 3
1996 4
1997 2
1998 5
1999 4
2000 7
2001 8
2002 7
2003 11
2004 14
2005 8
2006 16
2007 10
2008 14
2009 19
2010 16
2011 19
2012 21
2013 15
2014 19
2015 19
2016 16
2017 16
2018 25
2019 23
2020 18
2021 22
2022 24
2023 24
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

424 results

Results by year

Filters applied: . Clear all
Page 1
Approach to the patient with suspected hypereosinophilic syndrome.
Klion AD. Klion AD. Hematology Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):47-54. doi: 10.1182/hematology.2022000367. Hematology Am Soc Hematol Educ Program. 2022. PMID: 36485140 Free PMC article. Review.
Hypereosinophilic syndromes (HES) are a heterogenous group of rare disorders with clinical manifestations ranging from fatigue to life-threatening endomyocardial fibrosis and thromboembolic events. ...Primary (myeloid) disorders associated with hypereosinophilia are …
Hypereosinophilic syndromes (HES) are a heterogenous group of rare disorders with clinical manifestations ranging from fatigue to lif …
Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma.
Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, Busse WW, Ford L, Sher L, FitzGerald JM, Katelaris C, Tohda Y, Zhang B, Staudinger H, Pirozzi G, Amin N, Ruddy M, Akinlade B, Khan A, Chao J, Martincova R, Graham NMH, Hamilton JD, Swanson BN, Stahl N, Yancopoulos GD, Teper A. Castro M, et al. N Engl J Med. 2018 Jun 28;378(26):2486-2496. doi: 10.1056/NEJMoa1804092. Epub 2018 May 21. N Engl J Med. 2018. PMID: 29782217 Free article. Clinical Trial.
We assessed its efficacy and safety in patients with uncontrolled asthma. METHODS: We randomly assigned 1902 patients 12 years of age or older with uncontrolled asthma in a 2:2:1:1 ratio to receive add-on subcutaneous dupilumab at a dose of 200 or 300 mg every 2 weeks or m …
We assessed its efficacy and safety in patients with uncontrolled asthma. METHODS: We randomly assigned 1902 patients 12 years of age …
World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management.
Shomali W, Gotlib J. Shomali W, et al. Am J Hematol. 2022 Jan 1;97(1):129-148. doi: 10.1002/ajh.26352. Epub 2021 Oct 8. Am J Hematol. 2022. PMID: 34533850 Free article.
DISEASE OVERVIEW: The eosinophilias encompass a broad range of nonhematologic (secondary or reactive) and hematologic (primary or clonal) disorders with potential for end-organ damage. DIAGNOSIS: Hypereosinophilia (HE) has generally been defined as a peripheral blood eosin …
DISEASE OVERVIEW: The eosinophilias encompass a broad range of nonhematologic (secondary or reactive) and hematologic (primary or clonal) di …
The DRESS syndrome: a literature review.
Cacoub P, Musette P, Descamps V, Meyer O, Speirs C, Finzi L, Roujeau JC. Cacoub P, et al. Am J Med. 2011 Jul;124(7):588-97. doi: 10.1016/j.amjmed.2011.01.017. Epub 2011 May 17. Am J Med. 2011. PMID: 21592453 Review.
We used the RegiSCAR scoring system that grades DRESS cases as "no," "possible," "probable," or "definite" to classify cases reported in the literature. We also analyzed the clinical course and treatments of the cases. A total of 44 drugs were associated with the 172 cases …
We used the RegiSCAR scoring system that grades DRESS cases as "no," "possible," "probable," or "definite" to classify cases reported in the …
Dupilumab-Associated Adverse Events During Treatment of Allergic Diseases.
Kychygina A, Cassagne M, Tauber M, Galiacy S, Paul C, Fournié P, Simon M. Kychygina A, et al. Clin Rev Allergy Immunol. 2022 Jun;62(3):519-533. doi: 10.1007/s12016-022-08934-0. Epub 2022 Mar 11. Clin Rev Allergy Immunol. 2022. PMID: 35275334 Review.
Among the new biological therapies for atopic diseases, dupilumab is a fully human monoclonal antibody directed against IL-4Ralpha, the common chain of interleukin-4 and interleukin-13 receptors. Dupilumab showed clinical improvements in patients with atopic dermatitis, as …
Among the new biological therapies for atopic diseases, dupilumab is a fully human monoclonal antibody directed against IL-4Ralpha, the comm …
Severe Asthma and Biologics: Managing Complex Patients.
Matucci A, Micheletto C, Vultaggio A. Matucci A, et al. J Investig Allergol Clin Immunol. 2023 Jun 15;33(3):168-178. doi: 10.18176/jiaci.0856. Epub 2022 Sep 5. J Investig Allergol Clin Immunol. 2023. PMID: 36059229 Free article. Review.
Bronchial asthma is a chronic inflammatory disease of the respiratory tract that varies in terms of clinical presentations (phenotypes) and distinct underlying pathophysiological mechanisms (endotypes). ...We outline the clinical features of patients with severe ast …
Bronchial asthma is a chronic inflammatory disease of the respiratory tract that varies in terms of clinical presentations (phenotype …
Eosinophilia Induced by Blocking the IL-4/IL-13 Pathway: Potential Mechanisms and Clinical Outcomes.
Olaguibel JM, Sastre J, Rodríguez JM, Del Pozo V. Olaguibel JM, et al. J Investig Allergol Clin Immunol. 2022 Jun 20;32(3):165-180. doi: 10.18176/jiaci.0823. Epub 2022 May 6. J Investig Allergol Clin Immunol. 2022. PMID: 35522053 Free article. Review.
This review investigates plausible mechanisms of dupilumab-induced hypereosinophilia and review cases of symptomatic hypereosinophilia associated with dupilumab. ...When choosing the optimal biologic, it seems necessary to consider the presence of hypereosinophil …
This review investigates plausible mechanisms of dupilumab-induced hypereosinophilia and review cases of symptomatic hypereosinoph …
World Health Organization-defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management.
Shomali W, Gotlib J. Shomali W, et al. Am J Hematol. 2019 Oct;94(10):1149-1167. doi: 10.1002/ajh.25617. Am J Hematol. 2019. PMID: 31423623 Free article. Review.
DISEASE OVERVIEW: The eosinophilias encompass a broad range of non-hematologic (secondary or reactive) and hematologic (primary, clonal) disorders with potential for end-organ damage. DIAGNOSIS: Hypereosinophilia has generally been defined as a peripheral blood eosinophil …
DISEASE OVERVIEW: The eosinophilias encompass a broad range of non-hematologic (secondary or reactive) and hematologic (primary, clonal) dis …
A Review of Dupilumab-Induced Adverse Events to Dermatologists and the Potential Pathogenesis in the Treatment of Atopic Dermatitis.
Tsai JH, Tsai TF. Tsai JH, et al. Dermatitis. 2024 Jan-Feb;35(1):24-42. doi: 10.1089/derm.2022.0096. Epub 2023 May 19. Dermatitis. 2024. PMID: 37205852 Review.
We conducted a systematic literature research of the PubMed, Medline, and Embase databases to identify articles recording the clinical manifestation and potential pathogenesis of these adverse events with interests (AEIs) to dermatologists. ...The potential pathogenesis in …
We conducted a systematic literature research of the PubMed, Medline, and Embase databases to identify articles recording the clinical …
Management of Hypereosinophilic Syndromes.
Roufosse F. Roufosse F. Immunol Allergy Clin North Am. 2015 Aug;35(3):561-75. doi: 10.1016/j.iac.2015.05.006. Immunol Allergy Clin North Am. 2015. PMID: 26209900 Review.
The symptomatic hypereosinophilic patient must be approached in a stepwise manner, with thorough assessment to determine whether the hypereosinophilia itself is contributing to damage and disease manifestations (thereby defining a hypereosinophilic syndrome), and to identi …
The symptomatic hypereosinophilic patient must be approached in a stepwise manner, with thorough assessment to determine whether the hype …
424 results